- Amended Current report filing (8-K/A)
24 April 2010 - 6:10AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date of
earliest event reported):
February 12,
2010
MARTEK BIOSCIENCES CORPORATION
(Exact Name of
Registrant as Specified in its Charter)
Delaware
|
|
0-22354
|
|
52-1399362
|
(State or other
jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
6480
Dobbin Road
Columbia,
Maryland
|
|
21045
|
|
(410) 740-0081
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
|
(Registrants telephone
number including area
code)
|
(Former name or
former address, if changed
since last report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
On February 17,
2010, Martek Biosciences Corporation, a Delaware corporation, (Martek) filed
a Current Report on Form 8-K reporting the completion of the merger of
Pearl, LLC, a Delaware limited liability company and wholly-owned subsidiary of
Martek, with Charter Amerifit LLC, a Delaware limited liability company (Amerifit)
and all of its subsidiaries. The Current Report on Form 8-K/A amends and
supplements the Form 8-K noted above and is filed for the purpose of
providing financial statements and pro forma financial information pursuant to
Item 9.01 of Form 8-K.
Item 9.01. Financial Statements
and Exhibits
(a)
Financial Statements of Business Acquired
The audited consolidated
financial statements of Amerifit as of and for the year ended December 31,
2008 are attached hereto as Exhibit 99.1.
The unaudited interim
consolidated financial statements of Amerifit as of September 30, 2009 and
for the nine months ended September 30, 2009 and 2008 are attached hereto
as Exhibit 99.2.
(b)
Pro Forma Financial Information
Pro forma financial
information as of and for the year ended October 31, 2009 is attached
hereto as Exhibit 99.3.
(d)
Exhibits
Exhibit
No.
|
|
Description
|
23.1
|
|
Consent of
Deloitte & Touche LLP, Independent Auditors
|
|
|
|
99.1
|
|
Audited consolidated
financial statements of Amerifit as of and for the year ended
December 31, 2008, and Independent Auditors Report
|
|
|
|
99.2
|
|
Unaudited interim
consolidated financial statements of Amerifit as of September 30, 2009
and for the nine months ended September 30, 2009 and 2008
|
|
|
|
99.3
|
|
Unaudited pro forma
financial information as of and for the year ended October 31, 2009
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: April 23,
2010
|
MARTEK BIOSCIENCES CORPORATION
|
|
|
|
By:
|
/s/
Peter L. Buzy
|
|
|
Peter L. Buzy
|
|
|
Chief Financial Officer, Treasurer and
Executive
|
|
|
Vice President for Finance and
Administration
|
3
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
23.1
|
|
Consent of
Deloitte & Touche LLP, Independent Auditors
|
|
|
|
99.1
|
|
Audited consolidated
financial statements of Amerifit as of and for the year ended
December 31, 2008, and Independent Auditors Report
|
|
|
|
99.2
|
|
Unaudited interim
consolidated financial statements of Amerifit as of September 30, 2009
and for the nine months ended September 30, 2009 and 2008
|
|
|
|
99.3
|
|
Unaudited pro forma
financial information as of and for the year ended October 31, 2009
|
4
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2023 to Jul 2024